Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | SVP & CFO | April 10, 2026 | April 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date April 10, 2026 · Filed April 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 177,333 |
Ending reported balance
After 2026-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-10 · Exercise / conversion · Acquired 13,000 · Balance 182,981 Row 2 · 2026-04-10 · Tax withholding · Disposed 5,648 · Balance 177,333 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,000 |
Reported balance
After 2026-04-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-10 · Exercise / conversion · Disposed 13,000 · Balance 13,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 6, 2022 01:06 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 74,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013948 · doc4.xml · derivative · entry 1 Singleton Mark Leonard · CIK 0001914936 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,500 Underlying: Class A Common Stock · 74,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 21, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 21, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.